Antengene Gestione

Gestione criteri di controllo 2/4

Antengene Il CEO è Jay Mei, nominato in Aug2020, e ha un mandato di 4.25 anni. la retribuzione annua totale è CN¥ 16.77M, composta da 37.8% di stipendio e 62.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 26% delle azioni della società, per un valore di € 14.30M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 4 anni.

Informazioni chiave

Jay Mei

Amministratore delegato

CN¥16.8m

Compenso totale

Percentuale dello stipendio del CEO	37.8%
Mandato del CEO	4.3yrs
Proprietà del CEO	26.0%
Durata media del management	4.3yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jay Mei rispetto agli utili di Antengene?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CN¥530m
Mar 31 2024	n/a	n/a	-CN¥555m
Dec 31 2023	CN¥17m	CN¥6m	-CN¥581m
Sep 30 2023	n/a	n/a	-CN¥628m
Jun 30 2023	n/a	n/a	-CN¥676m
Mar 31 2023	n/a	n/a	-CN¥639m
Dec 31 2022	CN¥15m	CN¥6m	-CN¥601m
Sep 30 2022	n/a	n/a	-CN¥584m
Jun 30 2022	n/a	n/a	-CN¥567m
Mar 31 2022	n/a	n/a	-CN¥611m
Dec 31 2021	CN¥17m	CN¥5m	-CN¥656m

Compensazione vs Mercato: La retribuzione totale di Jay ($USD 2.32M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 472.15K ).

Compensazione vs guadagni: La retribuzione di Jay è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Jay Mei (59 yo)

4.3yrs

Mandato

CN¥16,774,000

Compensazione

Dr. Jay Mei, M.D. & Ph.D. is the Founder of Antengene Corporation and serves as Chairman and Chief Executive Officer since August 18, 2020. Dr. Mei has experience in clinical research and development of on...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jay Mei	Founder	4.3yrs	CN¥16.77m	26% € 14.3m
Donald Andrew Lung	CFO & Executive Director	4.4yrs	CN¥7.12m	Nessun dato
Eitan Liu	Chief Operating Officer	4.3yrs	Nessun dato	Nessun dato
Shimin Sun	Corporate VP and Head of Clinical Enabling Functions & Operational Excellence	no data	Nessun dato	Nessun dato
Thomas Karalis	Corporate VP & Head of Asia Pacific Region	4.6yrs	Nessun dato	Nessun dato
Dirk Hoenemann	VP and Head of Medical Affairs for APAC & Early Clinical Development	4.3yrs	Nessun dato	Nessun dato
Xiaojing Zhang	Chief Medical Officer	1.9yrs	Nessun dato	Nessun dato
Yang Cao	Joint Company Secretary	no data	Nessun dato	Nessun dato
Wai Chiu Wong	Joint Company Secretary	2.7yrs	Nessun dato	Nessun dato

4.3yrs

Durata media

47yo

Età media

Gestione esperta: Il team dirigenziale di 722 è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jay Mei	Founder	6.3yrs	CN¥16.77m	26% € 14.3m
Donald Andrew Lung	CFO & Executive Director	3.4yrs	CN¥7.12m	Nessun dato
Timothy M. Block	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Joseph Camardo	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Shaji K. Kumar	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jeffrey Barrett	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Robert Gale	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jing Qian	Independent Non-Executive Director	4yrs	CN¥487.00k	Nessun dato
Sheng Tang	Independent Non-Executive Director	4yrs	CN¥487.00k	Nessun dato
Rafael Fonseca	Independent Non-Executive Director	1.6yrs	CN¥193.00k	Nessun dato
Florence Houn	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Wei-Li Zhao	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

4.0yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 722 sono considerati esperti (durata media dell'incarico 4 anni).

Antengene Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Less than half of directors are independent

Antengene Corporation Limited Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Recent updates

South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country

Full year 2023 earnings released: CN¥0.94 loss per share (vs CN¥0.97 loss in FY 2022)

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Market cap size

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Less than half of directors are independent

Antengene Corporation Limited Announces Executive Changes

Less than half of directors are independent

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Less than half of directors are independent

Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018

Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Corporation Limited Announces Management Changes

Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial

National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China

Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media